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topical estrogen treatment 
Augments the Vaginal Response to 
Escherichia coli flagellin
Anna Stanton1,5,9, Catherine Mowbray  1,9, Marcelo Lanz1,6, Karen Brown3, Paul Hilton  3,4,8, 
Alison tyson-capper2, Robert S. pickard2,3,10, Ased S. M. Ali2,7 & Judith Hall1 ✉
The female climacteric or menopausal process characterised by reduced estrogen, associates with 
an increased risk of recurrent urinary tract infections (rUtis) linked to uropathogenic Escherichia coli 
(UPEC). Clinically, topical vaginal estrogen treatment has a prophylactic effect against such infections. 
The aim of this study was to investigate, in vitro, the effects of a topical estrogen treatment on 
vaginal epithelial responses following challenge with E.coli flagellin mimicking an UPEC challenge. 
Immortalised vaginal epithelial cells (VK2 E6/E7), modelling the vaginal epithelium were treated with 
either 4 nM 17β-estradiol (E) for seven days, 50 ng/ml E.coli flagellin (F) for 12 h, or 4 nM 17β-estradiol 
plus 50 ng/ml flagellin (E + F(12 h)). RNA was analysed by microarray gene profiling using the Illumina 
HumanHT-12 v 4 Expression Beadchip. Following E + F treatments expression of genes encoding host 
defence molecules including DEFβ4A, DEFB103A, LCN2 as well as those associated with keratinisation 
eg CNFN and SPRR family genes were significantly enhanced (P < 0.05) compared to either E or F 
treatments alone. Mutation of estrogen responsive elements (EREs) identified in the DEFβ4 gene 
promoter abolished the augmented gene expression suggesting estrogen functioned directly through 
a regulatory mechanism involving ESR1/2. Ingenuity pathway analyses also suggested the pro-
inflammatory cytokine IL-17A to regulate the vaginal host defences during infection. Pre-treating VK2 
E6/E7 cells with estrogen (4 nM) and challenging with 1L-17A & F (12 h) significantly enhanced DEFβ4, 
DEF103A and S100A7 expression (P < 0.05). Origins of vaginal IL-17 in vivo remain unclear, but patient 
biopsies support γδ T cells located within the vaginal epithelium. These data suggest that the vaginal 
antimicrobial response induced by flagellin activation of Toll-like Receptor 5 cell signalling is augmented 
following topical estrogen application.
Decreased circulating concentrations of the steroid hormone estrogen characterise the female climacteric, 
which in some women coincides with the onset of urogenital pathologies, including vaginal atrophy and rUTIs 
Topical vaginal estrogen treatments, but not systemic estrogen therapy have been shown to alleviate rUTIs in 
post-menopausal women1,2.
Uncomplicated rUTIs experienced by post-menopausal women are generally characterised as ascending 
infections that, in more than 75% of cases, link to Esherichia coli3. Such bacteria referred to as uropathogenic 
E.coli (UPEC) originate in the gut, colonise the vaginal epithelium and migrate via the urethra to the bladder 
where they cause symptomatic infections4,5. The infection process is facilitated by UPEC displaying factors such 
as flagella and pili, which support both motile and adherent phenotypes that underpin their virulence in the uri-
nary tract6. Protection of the female urogenital tract from such uropathogens, pre-menopausally, is mediated by 
an array of constitutive and induced host innate defence factors as well as the vaginal microbiota. This microbiota 
is dominated by Lactobacilli7,8, which metabolise glycogen derived simple sugars to lactic acid, resulting in an 
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acid micro-environment hostile to UPEC survival9. The post-menopausal state, in contrast, is associated with a 
more neutral vaginal pH, which supports UPEC persistence and colonisation, and coincides with an increased 
susceptibility to rUTIs10.
In murine models, rUTIs have also been explained by the presence of intracellular and quiescent E.coli com-
munities, establishing and residing within the bladder epithelium11. The intracellular location of these bacterial 
communities means they are protected from the host defences and the effects of externally administered antimi-
crobials, and their persistence provides a constant bacterial reservoir able to seed new infections. While there is 
limited, but direct evidence to support this infection model in post-menopausal women12, it does not easily align 
to clinical data showing vaginal topical treatments are associated with a reduced incidence of UTIs1,13.
The standard clinical treatment for rUTIs is antibiotics, but this option is complicated by the relative ineffec-
tiveness of multiple and prolonged courses that promote resistant strains of the main causative organism UPEC14. 
Pre-conditioning of the vaginal or urethral epithelium to hinder E.coli colonisation and migration represents an 
alternative treatment for rUTIs and one such treatment available to post-menopausal women suffering rUTIs is 
topical vaginal estrogen treatment1. Mechanisms proposed to explain how topical estrogen functions in protecting 
from rUTI include increased vaginal glycogen stores favouring colonisation of the epithelium by Lactobacilli15, a 
strengthening of the urothelial barrier and the increased antimicrobial capacity of the bladder defences16.
In vitro data also support the clinical observations that vaginal estrogen plays a key role in boosting the 
bladder innate defences with epithelial integrity and host effectors including the host defence peptide, human 
β-defensin-2(hBD2), elevated in response to topical treatments16,17. Analyses of vaginal biopsy material from 
post-menopausal women with vaginal atrophy and pro-lapse supports local estrogen therapy to impact epithelial 
structure and barrier function through increased expression of genes associated with cell proliferation, differen-
tiation and defence18 and extracellular matrix protein synthesis19. However, the effects of estrogen on the vaginal 
host innate defences particularly during periods associated with potential UPEC infections are less well described.
While topical vaginal estrogen treatments help protect against rUTIs not all women can tolerate the therapy 
with vaginal bleeding or spotting, vaginal irritation, burning and itching reported as common adverse events1. 
Therefore further knowledge of the mechanisms by which the steroid hormone functions to help protect against 
rUTIs is necessary; this information may help underpin the development of non-hormonal alternative topical 
treatments that mimic the protective effects of estrogen, but carry reduced side-effects. The aim of this study was 
to investigate the mechanisms by which estrogen influences the innate defences of the vaginal epithelium, par-
ticularly in response to flagellin challenge utilized to model a putative UTI.
Methods
Patient samples. The patient study protocol exploring the effects of estrogen on the vaginal defences 
was carried out following a minor project amendment to REC Reference 09/H0905/15 (Newcastle upon Tyne 
Hospitals NHS Trust R&D Reference 4841). Postmenopausal patients undergoing either hysterectomy or vagi-
nal prolapse surgery were recruited to the study from the Urogynaecology department of Newcastle upon Tyne 
Hospitals NHS Foundation Trust and provided written informed consent. Patients groups reflected those either 
prescribed vaginal estrogen treatment (Vagifem® [estradiol hemihydrate equivalent to estradiol] 10 mcg twice 
weekly (n = 41, median age of 57 years) or not (n = 53, median age of 60 years) (Table 1S). Each of the 94 patients 
donated vaginal fluid and tissue samples collected in accordance with relevant guidelines and regulations, and 
these were analysed either by ELISA or gene expression using qPCR.
VK2 E6/E7 cell culture and challenges. VK2 E6/E7 vaginal epithelial cells were cultured in Keratinocyte 
SFM media (Life Technologies) at 37 °C and 5% CO2. Cells were grown in 75cm2 flasks (Corning) before being 
passaged and seeded into either 6-well (5 × 105 cells), 12-well (1.2 × 105 cells) or 96-well plates (1 × 105 cells). To 
model patient vaginal estrogen treatments cells were pre-treated with either 4 nM estrogen ((2-hydroxypropyl)-β
-cyclodextrin encapsulated17β-estradiol) or cyclodextrin (vehicle control) equivalent (Sigma) for 7 days before 
challenge with either 50 ng/ml flagellin isolated from E. coli17 for up to 24 hours or phosphate buffered saline 
(PBS). Cell culture medium, vehicle control and estrogen were typically replaced every 48 hours.
VK2 cells were seeded into 12-well plates at a density of 1 × 105 cells/well in keratinocyte-SFM media and 
pre-treated with either 4 nM 17β-estradiol or 14.8 nM cyclodextrin for 7 days prior to challenge. At 80% conflu-
ency the cells were washed with PBS, 1 ml keratinocyte-SFM medium added and after 24 hours the cells chal-
lenged with 100 ng/ml IL-17A (Sigma, USA), or 100 μM Tris-HCL, pH 7.4 with 2.5 mM NaCl, and 50 ng/ml 
flagellin (minimum concentration of flagellin shown to induce an innate response) or PBS. After 24 hours the 
medium was removed, the cells washed with PBS, the RNA extracted using the SV Total RNA Isolation Kit 
(Promega) as per manufacturer’s instructions and RNA samples stored at −80 °C.
Microarray and qPCR analysis. VK2 E6/E7cells were treated with as follows: cyclodextrin (vehicle con-
trol) for 7 days plus/minus 12 h flagellin (50 ng/ml) challenge, estrogen (4 nM) for 7 days plus/minus 12 h flagellin 
challenge. RNA was extracted from the cells using the SV Total RNA Isolation Kit (Promega) as per manu-
facturer’s instructions and quality verified using an Agilent 2100 Bioanalyser. Samples were sent to Service XS 
(Netherlands) for microarray analysis using the Illumina HumanHT-12 v4 Expression Beadchip. Raw data were 
converted into fold change relative to control and presented as heatmaps in collaboration with the Newcastle 
University Bioinformatics Support Unit using the R software platform with Bioconductor20,21. Microarray data 
has been deposited in the Gene Expression Omnibus Database, accession number GSE135583. Genes were con-
sidered significantly different if a fold change ≥ +2 or −2 and P < 0.05 was recorded.
Biopsy RNA was also extracted using the SV Total RNA Isolation Kit (Promega) and RNA samples stored at 
−80 °C. Nucleic acid was quality checked and quantified by nanodrop as previously described17. Reverse tran-
scription of RNA (400 ng) was performed using random hexamers (Roche), MMLV Reverse Transcriptase and 
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RNase Inhibitor (Promega). Gene expression was quantified by qPCR using SYBR Green (Roche) with 0.5 μm 
primers on a LightCycler 480 (Roche) with each plate containing controls for verification of single target ampli-
fication using melt curve technology22. Data were normalised to the appropriate reference genes GAPDH and 
ATP5b17; primer sequences of target genes are shown in Table 2S.
Epithelial estrogen receptor analyses. VK2 E6/E7 cells seeded at a density of 1 × 105 cells/well were 
pre-treated with either 1 µM ICI 182,780 known as fulvestrant (Tocris Bioscience) or 0.1% DMSO vehicle and 
4 nM β-cyclodextrin encapsulated 17β-estradiol or cyclodextrin vehicle for up to 7 days. The culture medium, 
ICI 182,780, encapsulated 17β-estradiol or cyclodextrin were replenished every 48 hours and 24 hours before a 
flagellin 50 ng/ml or PBS challenge.
For G-protein coupled estrogen receptor (GPER) stimulation VK2 E6/E7 cells seeded at a density of 1 × 
105 cells/well were pre-treated with either 100 nM GI or 0.01% DMSO vehicle and 4 nM β-cyclodextrin encap-
sulated17β-estradiol or cyclodextrin vehicle 24 hours before a flagellin 50 ng/ml or PBS challenge. The culture 
medium, 17β-estradiol or cyclodextrin were replenished every 48 hours.
ELISA host defence peptide analyses. Vaginal fluid samples were analysed for hBD2, hBD3, LCN2 and 
SLPI by ELISA. hBD2 ELISA (Peprotech) – capture antibody 100 µg/ml, detection antibody 0.5 µg/ml, samples 
diluted 1:1; hBD3 ELISA – capture antibody 0.25 µg/ml (Abcam), detection antibody 1 µg/ml (Abcam), sam-
ples diluted 1:4; LCN2 ELISA (R&D systems) – capture antibody 2 µg/ml, detection antibody 25 ng/ml, samples 
diluted 1:49; SLPI ELISA (R&D systems) – pre-coated plates, as per manufacturer’s instructions, samples diluted 
1:79. Each plate included a standard curve and negative control. Plates were read using a FLUOstar Omega plate 
reader (BMG Labtech, Germany) at 450 nm with correction at 540 nm and blank-corrected values analysed using 
4-parameter curve fit.
ERE site directed mutagenesis and luciferase reporter assay. A 2030 bp sequence upstream of 
the DEFβ4 gene ATG start codon cloned into plasmid phBD-2-Luc (Promega) was used in analysing roles of 
putative estrogen response elements (ERE). Point mutations of putative EREs were generated using customised 
primers, a QuikChange II site-directed mutagenesis kit (Agilent, USA) (Table 2 S) and confirmed by sequencing 
(GeneVision, UK). Transfection of plasmids into VK2 E6/E7 cells was performed using the reverse transfection 
method. Briefly, 150 ng DNA and 0.5 µl Attractene (Qiagen) were added to 50 µl media (per well) and left for 
complex formation for 15 minutes. Cells were plated into 96-well clear bottomed plates at a density of 5 × 104 
cells/well in media supplemented with 4 nM 17β-estradiol or 14.8 nM cyclodextrin. The plasmid/attractene com-
plex was added and the cells left to adhere over-night. Following a media change, the cells were incubated for a 
further 24 hours and challenged with either flagellin (50 ng/ml) or PBS. Post-challenge, cells were lysed as per the 
Luciferase Assay System protocol (Promega) and luminescence read using a FLUOstar Omega Microplate reader 
(BMG Labtech).
Statistical analyses. Statistical analyses were performed using GraphPad Prism 6 software. Following data 
analyses by one or two way ANOVA multiple comparisons were performed using Dunnet’s, Sidak’s or Tukey’s 
post hoc tests.
Results
Estrogen and flagellin treatment of VK E6/E7 cells - microarray data. Microarray data relating to 
the E, F (12 h) and E + F (12 h) challenges were mined and gene probes shown to be differentially expressed in 
response to either estrogen pretreatment (E), or Flagellin (F12) and/or E + F12 treatments identified (Fig. 1A & 
B). Ontology analyses of these 270 probes identified up-regulation of expression pathways specifically related to 
innate immunity, cell differentiation and keratinization.
Notably five genes (Fig. 1B), LCN2, S100A8, S100A9, SPRR2A & SPRR2F encoding proteins involved in host 
defence and keratinisation were differentially expressed in response to each of the three treatments (E12, F12, 
and E + F12). All genes were upregulated (Fig. 1C) with the highest level of expression observed in response to 
E + F12. These data indicated that estrogen pretreatment of the VK2 E6/E7 cells prior to infection (F challenge) 
enhanced gene expression and augmented the host response.
F (12 h) and E + F (12 h) treatments significantly affected the expression of 124 common gene probes (Fig. 1B). 
Within this group were six gene probes that showed significantly fold higher expression following E + F12 treat-
ment compared to F12h treatment alone. Such genes included SPRR2D (5.73 v 2.09), SPRR2E (two probes) (10.8 v 
2.4; 13.53 v 3.14), DEFβ4 (2.35 v 5.11), IL36G (4.34 v 2.7) and SERPINB4 (6.48 v 2.92) encoding peptides and pro-
teins involved in vaginal keratinisation and host defence including the inflammatory response (Table 1). However, 
downregulation of gene expression was also detected in response to the E + F12 treatment. Examples included 
genes encoding the chemokines CXCL10 and CCL5 involved in the inflammatory response, which showed fold 
changes of 41.73 and 9.6, respectively, after F12 treatment but 16 and 4.56, following E + F12 treatment (Table 1).
Five gene probes were shown to be upregulated by E and E + F12 but not F12 treatments. Genes represented 
were CNFN, F3, LCE3D, SBSN and SLPI, which apart from F3, again encoded proteins linked to cell keratinisa-
tion, differentiation and host defence. These data supported estrogen functioning naturally to augment the cell 
defences as well as during periods of infection.
Data mining also identified 54 gene probes that were differentially expressed in response to E/F12, but neither 
E nor F12 treatments (Fig. 1B). All 54 probes showed significant upregulation and reflected molecules involved in 
host defence including, S100A7 (5.07 fold); WFDC5 (3.17); inflammation, CXCL14 (2.45) as well as cell differen-
tiation and keratinisation SPRR2C (5.77), SPRR2G (7.27), KRT1 (8.82 fold), KRT6C (2.95).
When the F challenges were repeated for 24 h rather than 12 h comparable changes in differential gene expres-
sion were observed (Figure S1A & B) although variations were detected. For example increased expression of 
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RNASE7 (1.9 v 5.4 fold), SPRR2C (5.77 v 19.5), and SPRR2G (7.27 v 22.6) were detected at 24 h following the E + F 
treatments (Fig. 1C; Table 1).
UPEC are characterised by flagella and the host Toll-like Receptor 5 (TLR5) pathway is key in detecting poten-
tial uropathogens and activating the urogenital innate defences17,23. Microarray data focussed on the TLR5 signal-
ling pathway suggested E, F12, E + F12 treatments did not affect expression of genes encoding proteins involved 
in TLR5 signalling except for the IRAK2 gene which was upregulated (>2 fold) in response to the E + F treatment 
(Fig. 1D).
Topical vaginal estrogen treatment of post-menopausal women - in vivo data. To ver-
ify the physiological significance of these in vitro data vaginal douche or biopsy samples from control and 
post-menopausal women using topical vaginal estrogen were analysed. Results (Fig. 2A–D) indicated that topical 
estrogen treatment increased the vaginal concentrations of host defence agents including LCN2 and SLPI, which 
supported the microarray data, but significant increases in the concentrations of the defensins hBD2 and hBD3 
(P < 0.05), were also observed. These latter observations were arguably more analogous to the E + F in vitro treat-
ments potentially reflecting the vaginal responses to the natural urogenital microbiota. Analyses of vaginal biop-
sies also supported increased S100A7 gene expression indicative of enhanced barrier integrity (P < 0.05) (Fig. 2E) 
but surprisingly SPRR2A and SPRR2E expression, indicative of keratinocyte cell differentiation, were comparable 
between the two cohorts (Fig. 2F,G). Analysis of patient vaginal biopsies for TLR5 gene expression revealed no 
significant differences between the control and estrogen treated cohorts (Fig. 2H).
Figure 1. (A) Heatmap showing differential gene expression patterns following 12 h treatments of VK2 E6/
E7 cells with vehicle (ctrl_12) (n = 3) and estrogen + flagellin (EF_12) (n = 3). Rows represent individual 
genes and their fold expression measurements while columns show different experimental conditions; genes 
are clustered according to patterns of expression and functionality (B) Venn Diagram illustrating differentially 
regulated genes following pre-treatment of VK2 E6/E7 cells with E (Green), F (12 h) (Blue) and E + F (12 h) 
(Pink). Genes upregulated in response to E + F but not E or F were KRT1, SPRR2G, SPRR2C, S100A7, DSG1, 
SERPINB3, S100P, TMEM45A, DSC1 (2 probes), TMEM45A, NCCRP1, WFDC5, KRT6C, KRTDAP, CYP4F22, 
ALOX12B, ZNF750, ID1, SPRR2B, SPRR1A, S100A12, FABP4, ALDH3B2, LOR, KRT80, IGFBP3, SLC5A1, 
KLK11, CXCL14, CLDN1, SPRR1B, IGFBP3, KRT10, EGR1, TSC22D3, TSC22D3, SIAE, THBS1, MAFB, KLK12, 
DEFB103A, SULT2B1, A2ML1, ZC3H12A, CRCT1, SPRR3, DLX5, TGM1, GJB2, HOPX, F3, KLK7, SULT2B1; 
Five genes each upregulated in response to E and F and E + F treatments were LCN2, S100A8, S100A9, SPRR2A, 
SPRR2F; (C) Microarray gene expression data (fold changes) relating to E pretreatment (green), F 12 & 24 h 
challenges (blue) and E + F12 & 24 h F challenges (red); (D) Expression of genes encoding TLR5 signalling 
pathway molecules: vehicle treated/control (black), estrogen (E) (light grey), flagellin (F) (diagonal stripes) and 
estrogen + flagellin (E + F) (dark grey).
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VK2 E6/E7 estrogen receptors and innate effector gene regulation. Estrogen functions through 
either a classical pathway whereby estrogen receptors interact with estrogen responsive elements (ERE) in the 
target gene promoter or through a non-classical mechanism involving the membrane estrogen receptor GPER24. 
VK2 E6/E7 cells express genes encoding the classical intracellular ESR1 (ER-α) and ESR2 (ER-β) steroid receptors 
and the G protein-coupled estrogen receptor (GPER) (confirmed by end-point PCR and sequencing). Incubating 
estrogen treated VK2 E6/E7 cells with fulvestrant (1 µM) to inhibit ESR1/2 functioning and challenging with F 
(50 ng/ml) inhibited the augmenting effects of estrogen on effector gene expression, although interestingly gene 
expression in response to UPEC flagellin was also markedly reduced (Fig. 3A–C).
Fulvestrant functions as an antagonist of ESR1/2 activity, but is also an agonist of GPER. Incubating estrogen 
treated cells with 100nM G-1, a selective GPER receptor agonist with no activity against ESR1/2 receptors and 
challenging with F did not impact effector gene expression (Fig. 3E–G).
The host defence peptide HBD2 encoded by the DEFβ4 gene plays a significant role in the urothelial innate 
defences17. Putative ERE response elements were identified in the 5’ regulatory region of the gene (Fig. 2S) so 
this gene was targeted for further investigation of the transcriptional mechanism. Challenging VK2 E6/E7 cells, 
transfected with 2Kbp of 5’ DEFβ4 gene regulatory sequence fused to a luciferase reporter, with flagellin resulted 
in a 12-fold increase in luciferase activity that increased to 27-fold following estrogen pre-treatment of the cells. 
Mutation of these putative ERE sites (Fig. 2S) inhibited any potentiation of reporter activity (Fig. 3H), but statis-
tical analyses of the WT (E + F) versus ERE1-6 mutation data did not support any redundancy, ERE 4 (P = 0.07) 
and ERE 6 (P = 0.055).
Gene Symbol Probe Fold Change Protein Function E F(12 h) E + F(12 h) F(24 h) E + F(24 h)
DEFB103A ILMN_1684308 β-defensin-3 Antimicrobial 1.40 1.41 2.17 2.02 7.00
DEFB4A ILMN_2048043 Β-defensin-2 Antimicrobial 0.98 2.35 5.11 2.94 8.43
LCN2 ILMN_1692223 Lipocalin-2 Antimicrobial 2.18 6.38 9.47 4.89 9.87
RNAse7 ILMN_1712849 Ribonuclease, RNAse A family, 7 Antimicrobial 1.46 1.33 1.97 2.08 5.41
SLPI ILMN_2114720 Secretory leukocyte peptidase inhibitor Antimicrobial 2.16 1.54 3.16 — 2.79
WFDC5 ILMN_2079042 WAP-four-diS core domain-5 Antimicrobial, Protease Inhibitor — — 3.17 — 2.94
S100A7 ILMN_1757351 S100 calcium binding protein A7/Psoriasin
Antimicrobial, Keratinisation, 
Inflammation 1.86 1.48 5.07 2.50 10.66
S100A8 ILMN_1729801 S100 calcium binding protein A8 Keratinisation, Inflammation 2.03 2.24 3.39 2.10 2.41
S100A9 ILMN_1750974 S100 calcium binding protein A9 Keratinisation, Inflammation 2.13 2.53 5.86 2.25 3.79
S100A12 ILMN_1748915 S100 calcium binding protein A12
Antimicrobial, Keratinisation, 
Inflammation 1.13 1.22 2.69 — 5.23
CNFN ILMN_1803838 Cornifelin Keratinisation 2.04 1.30 5.90 — 6.50
LCE3D ILMN_1718395 Late cornified envelope 3D Keratinisation 2.11 1.64 5.76 2.64 10.37
SBSN ILMN_1712759 Suprabasin Keratinisation 2.06 1.35 4.44 — 5.25
SPRR2A ILMN_1795359 Small proline-rich protein 2A Keratinisation 2.06 3.95 14.75 3.60 17.04
SPRR2C ILMN_2197577 Small proline-rich protein 2C Keratinisation 1.11 1.60 5.77 2.77 19.52
SPRR2D ILMN_2191967 Small proline-rich protein 2D Keratinisation 1.98 2.09 5.73 — 4.10
SPRR2E ILMN_2211018 Small proline-rich protein 2E Keratinisation 1.73 3.14/2.46 13.53/10.84 2.43 11.75
SPRR2F ILMN_1674367 Small proline-rich protein 2F Keratinisation 2.20 3.60 13.08 2.79 12.32
SPRR2G ILMN_1702127 Small proline-rich protein 2G Keratinisation 1.26 1.81 7.27 3.25 22.46
KRT1 ILMN_1735712 Keratin 1 Keratinisation — — 8.82 — 5.13
KRT6C ILMN_1754576 Keratin 6C Keratinisation — — 2.95 — 2.50
IL36G ILMN_2158713 Interleukin 36 gamma Inflammation 1.00 2.70 4.34 2.08 4.05
SERPINB4 ILMN_1782716
Serpin peptidase 
inhibitor clade B, 
member 4
Inflammation 1.03 2.92 6.48 — 3.42
CXCL10 ILMN_1791750/1791759 Chemokine ligand 10 Inflammation — 41.73 16.00 9.82 6.46
CCL5 ILMN_2098126/1773352 Chemokine (C-C motif) ligand 5 Inflammation — 9.60/6.30 4.56/3.12 4.22 3.04
Table 1. Microarray results of gene probes specifically encoding proteins/peptides involved in antimicrobial 
activity, keratinisation and inflammation ie epithelial barrier defence, and differentially expressed in relation to 
E + F (12/24 h) treatments.
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Estrogen and transcriptional regulation of the innate IL-17 defences. Ingenuity pathway analyses 
of the microarray data highlighted ‘The role of IL-17A in Psoriasis’ as the canonical pathway most activated fol-
lowing treatment of VK2E6/E7 cells with E + F (Table S3). This pathway describes IL-17A binding to the IL-17 
receptor complex (ILRA/RC) and transcription of genes including DEFβ4 and S100A7. Interestingly the vaginal 
Figure 2. Peptide concentrations of host defence agents measured in vaginal douche samples from control and 
estrogen treated patients (A) hBD2; (B) hBD3; (C) SLPI (D) LCN2 [n = 91, C = 50;E = 41]. Gene expression 
relating to (E) S100A7 (F) SPRR2A (G) SPRR2E (H) TLR5. mRNA expression presented as relative expression in 
vaginal biopsies from control and estrogen treated patients [n = 25, C = 14; E = 11]. * P < 0.05; **P < 0.01; *** 
P < 0.001.
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biopsies of the estrogen treated post-menopausal subjects were characterised by increased (P < 0.05) IL-17A, but 
not IL-17B expression (Fig. 4A,B). Residing within skin and mucosal epithelia are populations of innate T cells 
that produce IL-17 during periods of infection25. Expression (p = 0.06) of the transcription factor RORγt gene 
(Fig. 4C), in the estrogen treated vaginal biopsies did not, however, support increased numbers of vaginal IL-17 
producing T cells.
VK2 E6/E7 vaginal cells express the genes encoding IL-17 receptors, confirmed by PCR and DNA sequenc-
ing, and responded directly to recombinant IL-17A (0.1 to 100 ng/ml) through increased (P < 0.05) expression 
of genes encoding host antimicrobials (Fig. 5A–C). Estrogen pre-treatment of VK2 E6/E7 cells did not enhance 
Figure 3. Effects of fulvestrant treatment on DEFβ4 (A) DEFB103A (B) and S100A7 (C) expression in VK2 E6/
E7cells pretreated with estrogen, challenged with F or E + F [N = 3; n = 9]. Effects of G1 treatment on DEFβ4 
(D) DEFB103A (E) and S100A7 (F) expression in VK2 E6/E7 cells pretreated with estrogen, challenged with 
F or E + F [N = 2; n = 6]. (H) Effects of mutating EREs in the DEFβ4 promoter measured by luciferase activity 
and data normalised to a cyclodextrin-treated control [N = 4; n = 8]. Data presented as mean ± SEM. ns – not 
significant, **P < 0.01; *** P < 0.001.
Figure 4. IL-17A (A) IL-17B (B) RORγt (C), mRNA expression presented as relative expression in vaginal 
biopsies from control and estrogen treated patients [n = 25, C = 14; E = 11]. Data presented as mean ± SEM. 
*P < 0.05.
8Scientific RepoRtS |         (2020) 10:8473  | https://doi.org/10.1038/s41598-020-64291-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
these IL-17A effects, but synergistic effects were suggested when mimicking infection through the use of flagellin 
(Fig. 5D–F).
Discussion
The female climacteric is characterised by decreased circulating concentrations of estrogen, which in some 
women, coincide with an increased susceptibility to rUTIs peri and post menopausally. Topical vaginal estrogen 
helps reduce UTI incidence1,18 with the protective mechanisms being multifaceted and involving alterations in 
vaginal pH and microbiota composition15,26, the strengthening of the bladder epithelial barrier and the enhanced 
antimicrobial capacity of the urothelium16,17. Our clinical and in vitro data also supported topical estrogen as 
functioning to protect the vaginal epithelium through increased production of innate effector molecules and bar-
rier strengthening, but furthermore suggested that estrogen helps boost these vaginal defences through augmen-
tation of the TLR5 response to flagellin. Arguably this enhanced innate response reduces microbial colonisation 
of the vaginal regions and helps protect against flagellated microbes such as UPEC causing UTIs.
UTIs are associated with bacterial motility and flagellated uropathogens such as UPEC ascending into the 
bladder and causing UTIs27. Host urothelial cells are characterised by TLR5 receptors that detect UPEC flagella 
and their activation orchestrates the synthesis, and release of host innate effectors including cytokines and antimi-
crobials, which kill potential uropathogens17,28. Vaginal cells, characterised by both ESR and GPER proteins also 
exhibit TLR5 receptors29,30 suggesting that the estrogen associated boost in the vaginal TLR5/F effector responses 
results from either direct or indirect physical interactions between the different receptor types. Inhibitor studies 
supported the involvement of ESR1/2, but not the membrane located GPER, and suggested a direct molecular 
mechanism of gene regulation. This was confirmed by mutagenesis of putative ERE sites in the DEFβ4 promoter 
region. These data also supported ESR1/2 binding and NFκB signalling, the cellular response to flagellin chal-
lenge17, functioning synergistically to boost the vaginal innate defences. A comparable synergistic response, again 
involving DEFβ4 expression, but linked to lipopolysaccharide challenge has also been reported in primary vaginal 
cells pre-treated with estrogen31.
Promoters of other genes known to encode agents involved in the urogenital innate defences and including 
LCN2, RNASE7 and S100A7 are also characterised by putative EREs (Fig. 2S). Assuming similar regulatory mech-
anisms operate this illustrates, potentially, how reduced circulating estrogen concentrations associated with the 
climacteric associate with diminished epithelial defences, which expose the vaginal tissues to bacterial colonisa-
tion and/or repeated infections. ESR knockout mouse studies, which reported the reduced production of secre-
tory proteins, including the host defence agent lactoferrin in the uterine epithelial tissues32, suggest ESR1 (ERα) 
Figure 5. Effects of IL-17A peptide challenges on DEFβ4 (A), LCN2 (B) and RNase7 (C) gene expression in 
VK2 E6/E7 cells. Effects of IL-17A peptide 100 ng/ml on DEFβ4 (D) LCN2 (E) and RNAse7 (F) expression in 
VK2 E6/E7 pretreated with cyclodextrin ■ or estrogen  and challenged with F/IL-17A [N = 2; n = 6]. Data 
presented as mean ± SEM. ns – not significant; *P < 0.05; **P < 0.01; ***P < 0.001.
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activity to be key in the response. However, there is uncertainty as others have reported ESR2 (ERβ) as being more 
important in regulating the bladder antimicrobial response16.
It has been reported that estrogen treatment of vaginal epithelial cells (48 h) associates with decreased secre-
tion of the host defence molecules, hBD2 and elafin33. These observations are difficult to explain physiologically 
as decreased vaginal hBD2 concentrations are characteristic of post-menopausal women17. Moreover impaired 
elafin expression is related to stress urinary incontinence and pelvic organ prolapse, conditions again more reflec-
tive of women with low circulating estrogen concentrations34. One explanation for these anomalies relates to the 
cell models used, that is, freshly isolated vaginal cell preparations compared to vaginal biopsies or robust cell 
monolayers.
TLR5 is a key host factor in detecting potential UPEC infections17,28. Reports using human bladder T24 cells 
suggest that estrogen treatment is linked to TLR5 suppression with prolonged flagellin exposure further reducing 
TLR5 protein concentrations as measured by ELISA35. In contrast, our VK2 E6/E7 microarray data analysed in 
response to estrogen and E + F treatments did not suggest changes in TLR5 expression. Although paradoxical 
these two sets of data are consistent with receptor activation and dimerization, and the potential loss of antigenic 
binding sites available to TLR5 antibodies, which could be interpreted as reduced receptor protein. The vaginal 
biopsy data also revealed no changes in TLR5 gene expression in women using topical estrogen although expres-
sion has been previously shown to be significantly increased in post-menopausal women experiencing active 
UTIs17. These latter observations suggest factors other than estrogen and flagellin are involved in regulating TLR5 
expression in vivo.
Similar to published data18,19 the microarray analyses suggested that expression of a number of genes encod-
ing proteins involved in vaginal barrier integrity and thickening eg SPRR2A, SPRR2F, LCE3D and CNFN were 
significantly enhanced in response to estrogen treatment. Importantly our data also showed that expression of 
gene subsets, including those encoding proteins involved in keratinisation such as the small proline rich pro-
teins (Table 1), were further enhanced in response to flagellin, used experimentally to mimic an UPEC infec-
tion. These observations supported synergistic mechanisms functioning to help protect the integrity and barrier 
structure of the vaginal epithelium. It is of interest that peptide fragments called keratin-derived antimicrobial 
peptides (KDAMPs), have also been reported to act as antimicrobial agents in epithelial cells36. Vaginal estrogen 
treatments may therefore not only enhance resistance to infection through direct modifications of the epithelial 
barrier, but also through increased KDAMP production, hence augmenting the more traditional epithelial host 
innate defences.
Ingenuity pathway analyses of the microarray data highlighted a potential role for IL-17 in protecting the vag-
inal epithelium from microbial infections. This pro-inflammatory cytokine is linked to populations of innate-like 
lymphocytes including γδ T cells located within epithelial barriers37 and functions through direct induction of 
epithelial host defence agents and increased neutrophil recruitment25,38. While studies in mice have shown that 
vaginal fungal challenges are associated with increases in vaginal IL-17 concentrations that signal through epi-
thelial IL-17R to induce host defence peptides39 less is known of the roles, if any, of vaginal IL-17 in protecting 
against bacterial mediated UTIs. However, the fact that vaginal biopsies from post-menopausal women treated 
with topical estrogen hinted of increased T cell numbers, potentially γδ T cells, and IL-17A but not IL-17B gene 
expression, indicates a significant vaginal innate defence mechanism whose role(s) need further exploration in 
relation to UTI pathologies. Moreover the observation that the VK2 E6/E7 antimicrobial responses modelled 
in vitro using combinations of IL-17 and UPEC flagellin, could be enhanced in the presence of estrogen, again 
demonstrated the promiscuity of the steroid hormone in boosting the vaginal innate defences.
For flagellated uropathogens such as UPEC transiting from the gut to the bladder, the vaginal epithelium 
provides a potential colonisation site. These data show how estrogen plays key roles in directly enhancing a 
plethora of vaginal innate defence mechanisms that encompass epithelial integrity and antimicrobial potency 
and function collectively, to reduce or prevent microbial colonisation. These observations also help explain why 
post-menopausal women characterised by reduced estrogen concentrations are at increased risk of rUTIs asso-
ciated with flagellated UPEC.
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